Nuvectis Pharma, Inc.
Nuvectis Pharma is a clinical-stage biopharmaceutical company developing precision medicines for serious oncology conditions. Its main product candidate is NXP900, a small-molecule targeted therapy that inhibits SRC and YES1 kinases. Nuvectis licensed worldwide commercial rights to NXP900 from the University of Edinburgh and is evaluating it in a Phase 1b study as a single agent for specific tumor types and in combination with EGFR and ALK inhibitors. The company also licensed NXP800, another small-molecule cancer drug candidate, but ceased its clinical development in July 2025 and is assessing possible next steps. Nuvectis seeks to identify, license, develop and commercialize therapeutics, and aims to expand its product-candidate pipeline and pursue collaborations. Its business model centers on developing drug candidates for potential regulatory approval and commercialization. The company is headquartered in Fort Lee, New Jersey.
No SEC Form 4 filings for $NVCT in the last 30 days.
See all $NVCT insider activity →Nuvectis Pharma reported a Q3 2026 net loss of $30.1M, or $1.02 per share, with $140.7M in cash. The company made a $20M upfront license payment and achieved $1.8M in milestones. Cash runway extends into 2H 2029. Operating loss was $31M, with R&D expenses at $27.4M. Ciprocopan was approved in China, and Nuvectis is progressing regulatory discussions in the U.S.
Nuvectis Pharma, Inc. (NVCT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Nuvectis Pharma Reports Third Quarter 2026 Financial Results and Business Highlights · In-licensing of ex-China rights to two potentially best-in-class compounds (NXP100 and NXP200) from Haisco Pharmaceutical Group transformed Nuvectis into a late-stage clinical deve
Nuvectis Pharma (NASDAQ:NVCT) presented Phase 1b data for NXP200, a BRAF inhibitor, at the European Society for Medical Oncology Congress. 27 patients with gliomas showed a 40% response rate in high-grade and 42.9% in low-grade cases. The company plans to submit a U.S. IND application by year-end.
Over the past 7 days, AlphAI's AI scored 4 news stories mentioning NVCT (Nuvectis Pharma, Inc.). Coverage has skewed bearish: 1 bullish, 1 neutral, and 2 bearish.
Recent NVCT coverage spans earnings, technology and insider activity.
The earnings miss and sizable cash burn suggest short‑term downside pressure, though the cash runway to 2029 and upcoming IND filings provide some upside potential.
Positive clinical data and strong cash position suggest upside potential; FDA discussions may add volatility.
Positive trial data likely supports a near‑term price rally.
The quarter shows cost pressure from higher R&D, offset partly by lower G&A, likely reinforcing a cash-burn and runway risk premium for NVCT.
China approval for ciprocopan and a $115M follow-on offering extend runway while U.S. IND/marketing application work ramps.
AlphAI scores every news story that mentions NVCT with an AI model for sentiment and relevance, and aggregates insider trades from Nuvectis Pharma, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Nuvectis Pharma reported a Q3 2026 net loss of $30.1M, or $1.02 per share, with $140.7M in cash. The company made a $20M upfront license payment and achieved $1.8M in milestones. Cash runway extends into 2H 2029. Operating loss was $31M, with R&D expenses at $27.4M. Ciprocopan was approved in China, and Nuvectis is progressing regulatory discussions in the U.S.
2 min readNuvectis Pharma, Inc. (NVCT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Nuvectis Pharma Reports Third Quarter 2026 Financial Results and Business Highlights · In-licensing of ex-China rights to two potentially best-in-class compounds (NXP100 and NXP200) from Haisco Pharmaceutical Group transformed Nuvectis into a late-stage clinical deve
3 min readNuvectis Pharma (NASDAQ:NVCT) presented Phase 1b data for NXP200, a BRAF inhibitor, at the European Society for Medical Oncology Congress. 27 patients with gliomas showed a 40% response rate in high-grade and 42.9% in low-grade cases. The company plans to submit a U.S. IND application by year-end.
2 min readNuvectis Pharma (NVCT) reported a wider Q2 2026 net loss of $7.02 million, or $0.30 per share, versus $6.33 million a year earlier. Operating loss rose to $7.20 million. R&D costs increased to $4.68 million from $3.61 million, while G&A fell to $2.51 million from $2.98 million. NVCT shares were down 7.06% at $20.08.
2 min readNuvectis Pharma (NASDAQ: NVCT) reported Q2 2026 results and said it completed in-licensing ex-China rights to ciprocopan (NXP100) and NXP200 from Haisco. Ciprocopan received China marketing approval in July 2026 for PNH patients not previously treated with complement inhibitors. The company raised $115M gross in a July follow-on offering, extending cash runway into 1H 2029. Cash was $22.2M at June 30, 2026; net loss was $7.0M.
6 min readNuvectis Pharma, Inc. (NVCT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Nuvectis Pharma Reports Second Quarter 2026 Financial Results and Business Highlights · Completed in-licensing of ex-China rights to two potentially best-in-class compounds (NXP100 and NXP200) from Haisco Pharmaceutical Group (“Haisco”), transforming the company into
5 min readNuvectis Pharma (NVCT) said it licensed worldwide rights outside China to NXP100 and NXP200 from Haisco Pharmaceutical Group for $40M upfront plus up to $1.42B in milestones. NVCT cites Phase 3 results for NXP100 in PNH versus eculizumab: 59.5% vs 8.3% transfusion-free normal hemoglobin. Two China NMPA applications are under review, with decisions expected late 2026 to early 2027.
5 min readNuvectis Pharma (NASDAQ:NVCT) priced a $100 million public discounted stock offering at $20.00 per share, about 30% below Monday’s $28.53 close. The company will issue 5,000,000 shares and granted underwriters a 30-day option for up to 750,000 more shares. Shares fell ~25% premarket; closing expected around July 1, 2026.
3 min readMosseri Marlio Charles purchased 50,000 indirectly-held shares of Nuvectis Pharma, Inc. (NVCT) at $18.32 ($0.92M total) on 2026-06-30.
2 min readBENTSUR RON (Chairman & CEO) purchased 12,500 shares of Nuvectis Pharma, Inc. (NVCT) at $20.00 ($0.25M total) on 2026-06-30.
2 min read
